BPG is committed to discovery and dissemination of knowledge
Cited by in CrossRef
Number Cited Articles
1
Vincenzo B. Polsinelli, Lara Marteau, Sanjiv J. Shah. The role of splanchnic congestion and the intestinal microenvironment in the pathogenesis of advanced heart failureCurrent Opinion in Supportive and Palliative Care 2019; 13(1): 24 doi: 10.1097/SPC.0000000000000414
2
Y.-L. Wang, H.-J. He, X.-X. Xiao, Y. Lin, B.-Q. Wang, S.-L. Zhu, G.-S. Yang, S.-S. Huang, Q.-G. Yang. Letter: rifaximin is more than helping hepatic encephalopathy-it also saves livesAlimentary Pharmacology & Therapeutics 2017; 46(11-12): 1122 doi: 10.1111/apt.14353
3
Eric G Meissner. The Gut-Liver Axis in Hepatitis C Virus Infection: A Path Towards Altering the Natural History of Fibrosis Progression?Clinical Infectious Diseases 2018; 67(6): 878 doi: 10.1093/cid/ciy208
4
Alberto Nicoletti, Francesca Romana Ponziani, Marco Biolato, Venanzio Valenza, Giuseppe Marrone, Gabriele Sganga, Antonio Gasbarrini, Luca Miele, Antonio Grieco. Intestinal permeability in the pathogenesis of liver damage: From non-alcoholic fatty liver disease to liver transplantationWorld Journal of Gastroenterology 2019; 25(33): 4814-4834 doi: 10.3748/wjg.v25.i33.4814
5
Jasmohan S. Bajaj, Giovanni Barbara, Herbert L. DuPont, F. Mearin, Antonio Gasbarrini, Jan Tack. New concepts on intestinal microbiota and the role of the non-absorbable antibiotics with special reference to rifaximin in digestive diseasesDigestive and Liver Disease 2018; 50(8): 741 doi: 10.1016/j.dld.2018.04.020
6
Vincenzo B. Polsinelli, Arjun Sinha, Sanjiv J. Shah. Visceral Congestion in Heart Failure: Right Ventricular Dysfunction, Splanchnic Hemodynamics, and the Intestinal MicroenvironmentCurrent Heart Failure Reports 2017; 14(6): 519 doi: 10.1007/s11897-017-0370-8
7
Caio Pupin Rosa, Gustavo Andrade Brancaglion, Tatimara M. Miyauchi-Tavares, Patrícia Paiva Corsetti, Leonardo Augusto de Almeida. Antibiotic-induced dysbiosis effects on the murine gastrointestinal tract and their systemic repercussionsLife Sciences 2018; 207: 480 doi: 10.1016/j.lfs.2018.06.030
8
Edford Sinkala, Michael Vinikoor, Kanekwa Zyambo, Ellen Besa, Bright Nsokolo, Paul Kelly. Propranolol Reduces Portal Vein Diameter in Schistosomal Liver Disease with Portal Hypertension: A Prospective Cohort Study The American Journal of Tropical Medicine and Hygiene 2020; 102(4): 832 doi: 10.4269/ajtmh.19-0452
9
Francesca Romana Ponziani, Venanzio Valenza, Erida Nure, Giuseppe Bianco, Giuseppe Marrone, Antonio Grieco, Maurizio Pompili, Antonio Gasbarrini, Salvatore Agnes, Gabriele Sganga, Gianfranco D. Alpini. Effect of liver transplantation on intestinal permeability and correlation with infection episodesPLOS ONE 2020; 15(6): e0235359 doi: 10.1371/journal.pone.0235359
10
Daniela Campion, Ilaria Giovo, Paola Ponzo, Giorgio M Saracco, Federico Balzola, Carlo Alessandria. Dietary approach and gut microbiota modulation for chronic hepatic encephalopathy in cirrhosisWorld Journal of Hepatology 2019; 11(6): 489-512 doi: 10.4254/wjh.v11.i6.489
11
Beatrice Campanella, Massimo Onor, Tommaso Lomonaco, Edoardo Benedetti, Emilia Bramanti. HS-SPME-GC-MS approach for the analysis of volatile salivary metabolites and application in a case study for the indirect assessment of gut microbiotaAnalytical and Bioanalytical Chemistry 2019; 411(28): 7551 doi: 10.1007/s00216-019-02158-6
12
S. Mouri, C. Bouzbib, H. El Mourabit, A. Schaefer, F. Imbert-Bismut, D. Galanaud, S. Tripon, M. Mallet, M. Rudler, C. Housset, D. Thabut, N. Weiss. L’encéphalopathie hépatique, du diagnostic au traitement en 2016Réanimation 2016;  doi: 10.1007/s13546-016-1223-2
13
Francesca Romana Ponziani, Maria Assunta Zocco, Lucia Cerrito, Antonio Gasbarrini, Maurizio Pompili. Bacterial translocation in patients with liver cirrhosis: physiology, clinical consequences, and practical implicationsExpert Review of Gastroenterology & Hepatology 2018; 12(7): 641 doi: 10.1080/17474124.2018.1481747
14
Francesca Romana Ponziani, Alberto Nicoletti, Antonio Gasbarrini, Maurizio Pompili. Diagnostic and therapeutic potential of the gut microbiota in patients with early hepatocellular carcinomaTherapeutic Advances in Medical Oncology 2019; 11: 175883591984818 doi: 10.1177/1758835919848184
15
El-Sayed Ibrahim, Ayman Alsebaey, Hassan Zaghla, Sabry Moawad Abdelmageed, Khalid Gameel, Eman Abdelsameea. Long-term rifaximin therapy as a primary prevention of hepatorenal syndromeEuropean Journal of Gastroenterology & Hepatology 2017; 29(11): 1247 doi: 10.1097/MEG.0000000000000967
16
Alec B. Rezigh, Erin Armenia, Ting Li, Irene Soesilo. Rifaximin as a rare cause of rhabdomyolysis in cirrhosisClinical Case Reports 2018; 6(7): 1296 doi: 10.1002/ccr3.1583
17
Xin-Yue Lv, Hui-Guo Ding, Jun-Fu Zheng, Chun-Lei Fan, Lei Li. Rifaximin improves survival in cirrhotic patients with refractory ascites: A real-world studyWorld Journal of Gastroenterology 2020; 26(2): 199-218 doi: 10.3748/wjg.v26.i2.199
18
Loris R. Lopetuso, Marco Napoli, Gianenrico Rizzatti, Antonio Gasbarrini. The intriguing role of Rifaximin in gut barrier chronic inflammation and in the treatment of Crohn’s diseaseExpert Opinion on Investigational Drugs 2018; 27(6): 543 doi: 10.1080/13543784.2018.1483333
19
Ying Yuan, Xiaomei Wang, Xiangyi Xu, Yu Liu, Cancan Li, Meng Yang, Yiqing Yang, Zhenkun Ma. Evaluation of a Dual-Acting Antibacterial Agent, TNP-2092, on Gut Microbiota and Potential Application in the Treatment of Gastrointestinal and Liver DisordersACS Infectious Diseases 2020; 6(5): 820 doi: 10.1021/acsinfecdis.9b00374
20
Yoo Li Lim, Moon Young Kim, Yoon Ok Jang, Soon Koo Baik, Sang Ok Kwon. Rifaximin and Propranolol Combination Therapy Is More Effective than Propranolol Monotherapy for the Reduction of Portal Pressure: An Open Randomized Controlled Pilot StudyGut and Liver 2017; 11(5): 702 doi: 10.5009/gnl16478
21
Russell Rosenblatt, Amit Mehta, Shirley Cohen‐Mekelburg, Nicole Shen, David Snell, Catherine Lucero, Arun Jesudian, Brett Fortune, Carl V. Crawford, Sonal Kumar. The rise of Clostridioides difficile infections and fall of associated mortality in hospitalized advanced cirrhotics Liver International 2019; 39(7): 1263 doi: 10.1111/liv.14077
22
Kazuyuki Suzuki, Ryujin Endo, Yasuhiro Takikawa, Fuminori Moriyasu, Yutaka Aoyagi, Hisataka Moriwaki, Shuji Terai, Isao Sakaida, Yoshiyuki Sakai, Shuhei Nishiguchi, Toru Ishikawa, Hitoshi Takagi, Atsushi Naganuma, Takuya Genda, Takafumi Ichida, Koichi Takaguchi, Katsuhiko Miyazawa, Kiwamu Okita. Efficacy and safety of rifaximin in Japanese patients with hepatic encephalopathy: A phase II/III, multicenter, randomized, evaluator-blinded, active-controlled trial and a phase III, multicenter, open trialHepatology Research 2018; 48(6): 411 doi: 10.1111/hepr.13045
23
Simona Iacob, Diana Gabriela Iacob. Infectious Threats, the Intestinal Barrier, and Its Trojan Horse: DysbiosisFrontiers in Microbiology 2019; 10 doi: 10.3389/fmicb.2019.01676
24
Lianjun Yang, Bin Liu, Junchi Zheng, Jincheng Huang, Qinghao Zhao, Jinshi Liu, Zhihai Su, Min Wang, Zhifei Cui, Tingxuan Wang, Weicong Zhang, Qingchu Li, Hai Lu. Rifaximin Alters Intestinal Microbiota and Prevents Progression of Ankylosing Spondylitis in MiceFrontiers in Cellular and Infection Microbiology 2019; 9 doi: 10.3389/fcimb.2019.00044
25
Sara Montagnese, Francesco Paolo Russo, Piero Amodio, Patrizia Burra, Antonio Gasbarrini, Carmela Loguercio, Giulio Marchesini, Manuela Merli, Francesca Romana Ponziani, Oliviero Riggio, Carmelo Scarpignato. Hepatic encephalopathy 2018: A clinical practice guideline by the Italian Association for the Study of the Liver (AISF)Digestive and Liver Disease 2019; 51(2): 190 doi: 10.1016/j.dld.2018.11.035